The implant is only the size of a grain of rice. Photo via Getty Images

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

Houston-area researchers are innovating health and wellness solutions every day — even focusing on non-pandemic-related issues. Getty Images

These 3 Houston research projects are revolutionizing health science

Research roundup

Researchers across the world are coming up with innovative breakthroughs regarding the coronavirus, but Houston research institutions are also making health and wellness discoveries outside of COVID-19.

Here are three from Houston researchers from a muscular atrophy study from outer space to a research project that might allow blind patients to "see."

Houston Methodist's research on muscular atrophy in astronauts

Scientists are studying the effect of certain drugs to help preserve muscles in astronauts. Photo courtesy of Houston Methodist/Facebook

Houston Methodist researcher Alessandro Grattoni and his team published research on muscular atrophy in astronauts. The research was published in Advanced Therapeutics and focused on his 2017 RR-6 muscle atrophy study that was conducted on the International Space Station.

While the current standard practice for astronauts maintaining their muscles is working out over two hours a day, the research found that use of drugs could also help preserve muscles. On a SpaceX refuel mission, mice that were implanted with a "Nanofluidic Delivery System" were sent up to space and monitored, according to a report. The device gradually released small doses of formoterol, an FDA approved drug for use in bronchodilation that has also been shown to stimulate increased muscle mass.

University of Houston researcher tracking fear response to improve mental health treatment

The research could help advance wearable devices. Photo via uh.edu

University of Houston researchers are looking into the way the body responds to fear in order to enhance mental health treatment. Rose Faghih, assistant professor of electrical and computer engineering, and doctoral student Dilranjan Wickramasuriya in the Computational Medicine Lab (CML) are leading the project.

"We developed a mixed filter algorithm to continuously track a person's level of sympathetic nervous system activation using skin conductance and heart rate measurements," writes Faghih in the journal PLOS One. "This level of sympathetic activation is closely tied to what is known as emotional arousal or sympathetic arousal."

When this sympathetic nervous system is activated — sometimes known as the "fight or flight" response — the heart beats faster and more oxygen is delivered to the muscles, according to a press release. Then, the body begins to sweat in order to cool down.

"Using measurements of the variations in the conductivity of the skin and the rate at which the heart beats, and by developing mathematical models that govern these relationships, CML researchers have illustrated that the sympathetic nervous system's activation level can be tracked continuously," reports Faghih.

This algorithm could be used in a wearable electronic device that could be worn by a patient diagnosed with a fear or anxiety disorder.

Baylor College of Medicine's vision-restoring research

What if a device could see for you? Photo from Pexels

When someone loses their vision, it's likely due to damage to the eyes or optic nerve. However, the brain that interprets what they eyes sees, works perfectly fine. But researchers from Baylor College of Medicine have worked on a thesis that a device with a camera could be designed and implemented to do the seeing for the blind patient.

"When we used electrical stimulation to dynamically trace letters directly on patients' brains, they were able to 'see' the intended letter shapes and could correctly identify different letters," says Dr. Daniel Yoshor, professor and chair of neurosurgery in a press release. "They described seeing glowing spots or lines forming the letters, like skywriting."

Through a study supported by the National Eye Institute with both sighted and blind people using implanted devices, the investigators determined that the process was promising. According to the release, the researchers identified several obstacles must be overcome before this technology could be implemented in clinical practice.

"The primary visual cortex, where the electrodes were implanted, contains half a billion neurons. In this study we stimulated only a small fraction of these neurons with a handful of electrodes," says said Dr. Michael Beauchamp, professor and in neurosurgery, in the release.

"An important next step will be to work with neuroengineers to develop electrode arrays with thousands of electrodes, allowing us to stimulate more precisely. Together with new hardware, improved stimulation algorithms will help realize the dream of delivering useful visual information to blind people."

Houston researchers are commercializing their organ 3D printing technology, a local hospital has a tiny medical device with a big impact, and more in health tech. Jordan Miller/Rice University

3 health technologies developed in Houston that are changing the industry

Game changers

There's a huge opportunity for breakthrough medical technology in Houston thanks in large part to major universities, the Texas Medical Center, and other resources within health care startups.

From a new tiny implant that can deliver medicine into the patient remotely to printable human tissue, here are three health technologies coming out of Houston innovators to look out for.

Houston Methodist's tiny drug delivery implant

This tiny implant can have a big effect on patients. Courtesy of Houston Methodist

Houston Methodist nanomedicine researchers have developed an implant the size of a grape that can deliver medicine via a remote control. The device has applications in arthritis, diabetes, and heart disease treatment.

The battery-powered nanochannel deliver system uses Bluetooth technology and can dole out continuous, predetermined dosages for up to a year without refills. A proof-of-concept for the device published in Lab on a Chip.

"We see this universal drug implant as part of the future of health care innovation," says Alessandro Grattoni, chair of the nanomedicine department at Houston Methodist. "Some chronic disease drugs have the greatest benefit of delivery during overnight hours when it's inconvenient for patients to take oral medication. This device could vastly improve their disease management and prevent them from missing doses, simply with a medical professional overseeing their treatment remotely."

The devices can be programed for different dosage sizes and different release settings, which affect the voltage for the medicine delivery.

Houston Methodist has a number of new technologies it's introduced into its hospital system — click here to read about a few more.

NurseDash's resourceful scheduling tool

Houston-based NurseDash is the Uber of staffing nursing shifts in medical facilities. Photo via nursedash.com

Filling open nursing shifts has always been a challenge for hospitals and medical centers, and they've been forced to rely on outsourced companies to coordinate nurses to fill the shifts. NurseDash puts the power back in the hands of freelance nurses and the medical institutions that want to hire them.

Andy Chen, former CFO for Nobilis Health Corporation and co-founder of NurseDash, says the standard practice is hiring these agencies to fill shifts, and, while they promise to send someone, they don't even know who they'll be sending for a shift just hours away. This antiquated system prioritizes who comes in first, rather than a nurse's specialties or qualifications.

Since its debut, NurseDash, which is based in Houston's Galleria Area, has attracted 40 facilities in Houston, including hospitals, surgery centers, and senior living, and about 400 nurses. Chen says he isn't sure just what to call his technology yet, but compares it to the ride hailing of Uber or Lyft and calls it "a virtual bulletin board."

The company has already expanded beyond Houston to northeast Ohio, which the founders say has a similar competitive dynamic to the Houston market. The next goal is to hit the rest of the top 10 largest cities in the United States. To read more about the app and startup, click here.

Volumetric's human tissue-printing technology

Rice University bioengineer Daniel Sazer prepares a scale-model of a lung-mimicking air sac for testing. Jeff Fitlow/Rice University

In a world where organ transplants means an incredible amount of time, money, and patience, there might soon be another option on the operating table. Volumetric is a startup that came out of a human tissue-printing technology developed at Rice University.

Jordan Millar developed the 3D printer in his lab at Rice, and still has ongoing research within the technologies. However, Miller says he very strategically chose to launch a for-profit company in 2018 — mainly, to provide access.

"If we want to do translational research, commercialization is important," reasons Miller. "We need to build the market to get that technology into the world."

Right now, the device is printing scaled down organs, and a contraption that looks a bit like a futuristic beehive, graced the cover of the May 3 issue of the journal Science. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. To read more about Volumetric, click here.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

6 exciting Houston startup raises to know from July 2026

fresh funding

Houston startups carried the fundraising momentum of Q1 and Q2 into July with several significant seed funding, Series A and Series B rounds.

From geothermal leaders to medtech innovators, these six Houston companies raised more than a quarter billion dollars last month alone, according to reporting by InnovationMap and our sister site, EnergyCapitalHTX.com.

Did we miss a funding round? Let us know by emailing innoeditor@innovationmap.com.

Altillion

Houston-based startup Altillion has secured $5 million in seed funding to accelerate the commercialization of its proprietary IRIS and ALIX technologies, which convert oilfield-produced water into valuable minerals, the company reported earlier this month.

San Francisco-based EIC Rose Rock and Houston-based Flathead Forge led the round. Altillion says the funding will go toward pilot facilities and commercial deployments as the company looks to scale in the U.S. Continue reading.

Buildforce

The U.S. is grappling with a current shortage of 50,000 electricians, according to the National Electrical Contractors Association. Photo via Unsplash

Houston-based Buildforce, which provides a tech-enabled staff platform geared toward electricians and electrical contractors, closed a $10 million Series A round led by Houston’s Saepio Capital last month.

Other investors in the round include Blue Heron Capital, Revolution’s Rise of the Rest Seed Fund, S3 Ventures and Chicago Ventures.

Buildforce says the funding will help fuel its national expansion and further development of its technology.

The startup, founded in 2019, connects electricians with electrical contractors for commercial and industrial construction projects. Continue reading.

Hephae Energy Technology Corp.

The company develops ultra-high-temperature tools to withstand the heat of geothermal reservoirs. Photo via hephaeet.com

Houston-area startup Hephae Energy Technology Corp. closed a $17.8 million Series A financing round last month to commercialize its geothermal technology.

The round was co-led by Pennsylvania-based Susquehanna Sustainable Investments, which invests in early-stage climatech companies, and Copenhagen-based Underground Ventures, which focuses on geothermal energy startups. Alfa8, Baruch Future Ventures, Centaurus Capital LP, Elemental Impact, Exa Ventures, Future Ventures, Grantham Foundation for the Protection of the Environment, New System Ventures and True North Institute joined the round, along with existing Houston-based investor Nabors Industries. Hephae reports in a news release that the Series A round brings the company's total capital raised to $24.7 million. Continue reading.

TYBR Health

The company's B3 GEL System is designed to protect tendons, ligaments and muscles while they heal from orthopedic surgery. Photo via Unsplash

Houston-based healthtech startup TYBR Health has raised a $30 million Series A round to scale its B3 GEL System, which helps protect tendons from scarring after surgery, the company announced last month.

The round was led by Minneapolis-based Vensana Capital and Cleveland-based Mutual Capital Partners, with participation from Denver-based Neovate Capital Partners and existing investors, according to a news release from the company.

TYBR Health said it plans to use the funding to broaden the B3 GEL System's clinical applications, expand commercialization and conduct studies to evaluate its ability to protect tissue and improve healing outcomes. Continue reading.

Venus Aerospace 

Venus Aerospace has secured funding from Mercury Fund, Lockheed Martin Ventures and others. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace closed a $91 million Series B round last month and plans to scale the production of its hypersonic engine.

The round was led by Houston-based Mercury Fund with participation from Lockheed Martin Ventures, MESH, PEAK6, Draper Associates, Starboard Star Venture Capital, Green Sands Equity and other investors, according to a news release.

The investment comes about a year after Venus completed the first U.S. flight test of its high-thrust rotating detonation rocket engine (RDRE). The engine is expected to enable vehicles to travel four to six times the speed of sound from a conventional runway and is about 15 percent more efficient than traditional alternatives, according to the company. Continue reading.

Quaise Energy

A rendering of a Quaise Energy geothermal plant. Rendering via quaise.com

Houston-based Quaise Energy, a producer of utility-scale geothermal power, closed $134 million in a Series B round last month to advance its “superhot” geothermal power plant.

Climate-focused San Francisco-based investment firm Prelude Ventures led the round, with participation from JERA Co., Japan’s largest power generation company, and Idemitsu Kosan, one of Japan’s largest energy companies. Nearly all existing investors, including cleantech-focused investment firm Safar Partners, participated in the round.

The startup expects more equity and debt deals to close “imminently.” Quaise has raised $230 million since its founding in 2018. Continue reading.

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.